Cell Source Business
Product stage
Clinical Trial
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentBiomaterials & Tissue Engineering
Target Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnology
Core Technology
BiologicalsCells
Tags (6)
immunologybiological-therapyregenerative-medicinecell-therapycancerpharma-companies
Geographic Markets
United States
Cell Source News
2 articles
Cell Source Presents Potential Breakthrough in the Development of Off-the-Shelf CAR-T Cell Therapy at American Society of Hematology Annual Meeting
Cell Source, Inc. presented promising preclinical findings at the 2024 American Society of Hematology Annual Meeting, showcasing their Veto Cell technologys ability to overcome NK cell-mediated rejection, a significant barrier in allogeneic cell therapy. This innovation could lead to safer, less costly, and more scalable off-the-shelf CAR-T therapies. The study demonstrated that Veto Tcm cells can suppress NK cell activity without adverse effects, enhancing the safety and efficacy of allogeneic CAR-T therapies. These findings align with Cell Sources vision of advancing immune tolerance to facilitate safer mismatched donor stem cell transplants and organ transplantation. The research represents a significant step towards overcoming challenges in developing off-the-shelf CAR-T cell therapies, a critical area in cancer immunotherapy.
Cell Source Shares Promising Interim Results From Groundbreaking Veto Cell Clinical Trial
Cell Source, Inc. announced positive interim results from its Phase 1/2 clinical trial using its Veto Cell technology for stem cell transplants. Conducted at The University of Texas MD Anderson Cancer Center, the trial involved 15 patients and demonstrated both safety and efficacy, with no severe graft-versus-host disease or toxicity linked to Veto Cells. This breakthrough suggests a safer, more patient-friendly approach to stem cell therapy, potentially transforming treatment for various hematologic conditions. The results were previously presented at the American Society for Hematology Annual Meeting. The findings highlight the potential of Veto Cells to improve access to life-saving transplants, aligning with the strategic goals of Cell Source. The success in this area mirrors the market potential seen in companies like Kite Pharma and Juno Therapeutics, which were acquired for substantial amounts following similar clinical achievements.
Cell Source Team
Yoram Drucker
Chairman of the Board
Employee Info
| Employees (range) | 11-50 |
| Exact count | 20 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 10 classification IDs that could be used for matching.
